ArticleAmerican journal of preventive cardiology2026
Trends in heart failure-related mortality among breast cancer patients in the United States from 1999 to 2024.
Article in American journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is a paucity of data among women with breast cancer and heart failure (HF)-related mortality trends based on race, ethnicity, and geographic regions in the United States. Objective: To investigate the trends in HF-related mortality among breast cancer patients aged ≥25 years. Methods: This retrospective analysis utilized mortality data from the US Centers for Disease Control and Prevention (CDC) Wide-ranging Online Data for Epidemiologic Research (WONDER) database from 1999 to 2024. We analyzed temporal trends in the HF-related mortality in breast cancer patients aged ≥25 years. Crude (CMRs) and age-adjusted mortality rates (AAMRs) per 100,000 people with the associated annual percentage change (APC) and 95% confidence intervals (CIs) were calculated. Joinpoint regression was used to analyze trends across the overall sample and various demographic and geographic subgroups. Results: Between 1999 and 2024, 8398 death certificates identified HF as the primary cause and breast cancer as a contributory cause, resulting in an AAMR of 0.139 per 100,000. The overall AAMR significantly declined from 1999 to 2014 (APC: -5.443%, 95% CI: -6.436 to -4.440), followed by a significant increase from 2014 to 2024 (APC: 6.299%; 95% CI: 4.475 to 8.155). Racial disparities were noted, with NH Black patients exhibiting the highest AAMR of 0.176 (95% CI: 0.121 - 0.248). Geographical differences were also observed, with Mississippi having the highest AAMR of 0.324 (95% CI: 0.270 - 0.379) and Florida having the lowest AAMR of 0.053 (95% CI: 0.045 - 0.061). Additionally, from 1999 to 2020, nonmetropolitan areas consistently showed higher AAMRs than metropolitan areas with rates of 0.159 (95% CI: 0.151 - 0.168) and 0.119 (95% CI: 0.116 - 0.123), respectively. Among the age groups, the highest CMR was observed in patients aged ≥85 years (CMR: 4.859). Conclusion: The persistent rise in HF-related mortality, especially pronounced among NH Black patients and in specific geographic locales, underscores the need for enhanced collaborative efforts across oncology, cardiology, cardio-oncology, public health, and policy domains to lessen disparities and improve the overall health outcomes of breast cancer survivors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.